Celgene is buying autoimmune disease therapeutics firm Delinia for $300 million upfront to expand its own inflammation and immunology pipeline with Delinia's lead preclinical-stage regulatory T cell (Treg) therapy. Delinia shareholders could receive another $475 million from Celgene in future development, regulatory, and commercial milestones. The transaction is expected to close during Q1 2017.
Delinia lead candidate DEL106 is an interleukin-2 (IL-2) mutein Fc fusion protein that acts as a Treg IL-2 receptor agonist. The protein is designed to upregulate Tregs and so restore immune system balance. Delinia suggests DEL106 could potentially be used to treat a range of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.
--From Genetic Engineering & Biotechnology News. Read full story